Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPrabahran, Ashvind-
dc.contributor.authorTacey, Mark A-
dc.contributor.authorFleming, Shaun-
dc.contributor.authorWei, Andrew-
dc.contributor.authorTate, Courtney-
dc.contributor.authorMarlton, Paula-
dc.contributor.authorWight, Joel C-
dc.contributor.authorGrigg, Andrew P-
dc.contributor.authorTuckfield, Annabel-
dc.contributor.authorSzer, Jeff-
dc.contributor.authorRitchie, David-
dc.contributor.authorChee, Lynette-
dc.identifier.citationEuropean journal of haematology 2018; online first: 2 Mayen_US
dc.description.abstractCore-binding factor acute myeloid leukaemia (CBF AML) defined by t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22) has a favourable prognosis, however 30-40% of patients still relapse after chemotherapy. We sought to evaluate risk factors for relapse in a de novo CBF AML cohort. A retrospective review of patients from 4 Australian tertiary centres from 2001-2012, comprising 40 t(8;21) and 30 inv(16) AMLs. Multivariate analysis identified age (p=0.032) and WCC>40 (p=0.025) as significant predictors for inferior OS and relapse respectively. Relapse risk was higher in the inv(16) group vs the t(8;21) group (57% vs 18%, HR 4.31, 95% CI: 1.78-10.42, p=0.001). Induction therapy had no bearing on OS or relapse free survival (RFS) however, consolidation treatment with >3 cycles of intermediate/high dose cytarabine improved OS (p=0.035) and relapse-free survival (RFS) (p=0.063). 5 patients demonstrated post-treatment stable q PCR positivity without relapse. (1)>3 consolidation cycles of intermediate/ high-dose cytarabine improves patient outcomes. (2)Age and inv(16) CBF AML subtype are predictors of inferior OS and RFS respectively. (3)Stable low-level MRD by qPCR does not predict relapse. (4)Similar OS in the inv(16) cohort compared to the t(8;21) cohort, despite a higher relapse rate, confirms salvageability of relapsed disease. This article is protected by copyright. All rights reserved.en_US
dc.subjectAcute Myeloid Leukaemiaen_US
dc.subjectCore binding factorsen_US
dc.titlePrognostic Markers in Core-Binding Factor AML and Improved Survival with Multiple Consolidation Cycles of Intermediate/High-dose Cytarabine.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleEuropean journal of haematologyen_US
dc.identifier.affiliationMelbourne Epicentre Royal Melbourne Hospital Victoria, Australiaen_US
dc.identifier.affiliationThe Alfred Hospital Victoria, Australiaen_US
dc.identifier.affiliationPrinces Alexandra Hospital Queensland, Australiaen_US
dc.identifier.affiliationAustin Healthen_US
dc.identifier.affiliationDepartment of Clinical Haematology and Bone Marrow, Transplant Royal Melbourne Hospital Victoria, Australiaen_US
dc.type.austinJournal Article-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.cerifentitytypePublications- Oncology- Newton-John Cancer Wellness and Research Centre- Haematology- Newton-John Cancer Wellness and Research Centre- Newton-John Cancer Wellness and Research Centre- Haematology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jun 7, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.